Dr. Reddy's Laboratories launches Hydroxychloroquine Sulfate Tablets
Myequity news service | Date : 12-07-2018 18:30:00 IST
Dr. Reddy's Laboratories Limited, announced that it has launched Hydroxychloroquine Sulfate Tablets USP, 200 mg, a therapeutic equivalent generic version of Plaquenil (hydroxychloroquine sulfate) Tablets, in the U.S. market, approved by the U.S. Food and Drug Administration (USFDA).
According to IMS Health, Plaquenil brand and generic had sales of USD 215 mn in the US market for the period of 12 months ending in May 2018.
These Hydroxychloroquine Sulfate Tablets are available in 200 mg tablets in the bottle count sizes of 100 and 500.
Plaquenil is a trademark of Concordia International Corp and is used to treat or prevent malaria , a disease caused by parasites that enter the body through the bite of a mosquito. About Dr. Reddy's:
Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APls, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dennatology.
Dr. Reddy's Laboratories Ltd closed 2.21% up at Rs 2352.30